Three years of experience:the Italian registry and safety data update.

Giovanni Savettieri; null Mancardi; null Laroni; Carlo Piccinni; Laura Periotto; Marisa De Rosa; Rosamaria Iommelli; null Drago; Patrizia Popoli; null Tomino; null Tomino; Anna Covezzoli; null Provinciali; null Tomino; Nicola Montanaro; Nicola Vanacore; Clara Milanese; null Popoli; null Pozzilli; Giovanni Savettieri; Antonio Bertolotto; null Marrosu; null Tola; Luigi M.E. Grimaldi; null Provinciali; Gioacchino Tedeschi; Roberto D'Alessandro; Maria Pia Amato; null Comi; null Rossi

Three years of experience:the Italian registry and safety data update.

Giovanni Savettieri, Mancardi, Laroni, Carlo Piccinni, Laura Periotto, Marisa De Rosa, Rosamaria Iommelli, Drago, Patrizia Popoli, Tomino, Tomino, Anna Covezzoli, Provinciali, Tomino, Nicola Montanaro, Nicola Vanacore, Clara Milanese, Popoli, Pozzilli, Giovanni SavettieriAntonio Bertolotto, Marrosu, Tola, Luigi M.E. Grimaldi, Provinciali, Gioacchino Tedeschi, Roberto D'Alessandro, Maria Pia Amato, Comi, Rossi

Risultato della ricerca: Article › peer review

28 Citazioni (Scopus)

Abstract

At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%.Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability was documented.

Lingua originale	English
pagine (da-a)	295-297
Numero di pagine	3
Rivista	Neurological Sciences
Volume	31
Stato di pubblicazione	Published - 2011

All Science Journal Classification (ASJC) codes

???subjectarea.asjc.2700.2708???
???subjectarea.asjc.2700.2728???
???subjectarea.asjc.2700.2738???

Altri file e collegamenti

OA Link

Cita questo

Savettieri, G, Mancardi, Laroni, Piccinni, C, Periotto, L, De Rosa, M, Iommelli, R, Drago, Popoli, P, Tomino, Tomino, Covezzoli, A, Provinciali, Tomino, Montanaro, N, Vanacore, N, Milanese, C, Popoli, Pozzilli, Savettieri, G, Bertolotto, A, Marrosu, Tola, Grimaldi, LME, Provinciali, Tedeschi, G, D'Alessandro, R, Amato, MP, Comi & Rossi 2011, 'Three years of experience:the Italian registry and safety data update.', Neurological Sciences, vol. 31, pagg. 295-297.

@article{dd3f6825d93e424d90fb2c410720350c,

title = "Three years of experience:the Italian registry and safety data update.",

abstract = "At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%.Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability was documented.",

keywords = "Multiple sclerosis, Natalizumab, Pharmacovigilance, Surveillance program, Multiple sclerosis, Natalizumab, Pharmacovigilance, Surveillance program",

author = "Giovanni Savettieri and Mancardi and Laroni and Carlo Piccinni and Laura Periotto and {De Rosa}, Marisa and Rosamaria Iommelli and Drago and Patrizia Popoli and Tomino and Tomino and Anna Covezzoli and Provinciali and Tomino and Nicola Montanaro and Nicola Vanacore and Clara Milanese and Popoli and Pozzilli and Giovanni Savettieri and Antonio Bertolotto and Marrosu and Tola and Grimaldi, {Luigi M.E.} and Provinciali and Gioacchino Tedeschi and Roberto D'Alessandro and Amato, {Maria Pia} and Comi and Rossi",

year = "2011",

language = "English",

volume = "31",

pages = "295--297",

journal = "Neurological Sciences",

issn = "1590-1874",

publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - Three years of experience:the Italian registry and safety data update.

AU - Savettieri, Giovanni

AU - Mancardi, null

AU - Laroni, null

AU - Piccinni, Carlo

AU - Periotto, Laura

AU - De Rosa, Marisa

AU - Iommelli, Rosamaria

AU - Drago, null

AU - Popoli, Patrizia

AU - Tomino, null

AU - Covezzoli, Anna

AU - Provinciali, null

AU - Tomino, null

AU - Montanaro, Nicola

AU - Vanacore, Nicola

AU - Milanese, Clara

AU - Popoli, null

AU - Pozzilli, null

AU - Savettieri, Giovanni

AU - Bertolotto, Antonio

AU - Marrosu, null

AU - Tola, null

AU - Grimaldi, Luigi M.E.

AU - Provinciali, null

AU - Tedeschi, Gioacchino

AU - D'Alessandro, Roberto

AU - Amato, Maria Pia

AU - Comi, null

AU - Rossi, null

PY - 2011

Y1 - 2011

N2 - At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%.Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability was documented.

AB - At the end of 2006, a pharmacovigilance program on natalizumab was settled by the Italian Pharmaceutical Agency, and on January 2007, multiple sclerosis patients poorly responding to the immunomodulating therapies or with an aggressive clinical form of disease from onset initiated to be registered and to receive the medication. On February 2010, almost 3,000 cases have been treated with natalizumab. The drop-out rate is 10%.Almost 800 cases received cycles of natalizumab for more than 18 months. One case of PML was reported and other adverse events are similar to those described in phase III studies. The majority of cases remained stable, while in 25% of cases, an improvement of disability was documented.

KW - Multiple sclerosis

KW - Natalizumab

KW - Pharmacovigilance

KW - Surveillance program

KW - Multiple sclerosis

KW - Natalizumab

KW - Pharmacovigilance

KW - Surveillance program

UR - http://hdl.handle.net/10447/55523

M3 - Article

SN - 1590-1874

VL - 31

SP - 295

EP - 297

JO - Neurological Sciences

JF - Neurological Sciences

ER -

Three years of experience:the Italian registry and safety data update.

Abstract

All Science Journal Classification (ASJC) codes

Altri file e collegamenti

Fingerprint

Cita questo